Mechanisms of foam cell formation in atherosclerosis

DA Chistiakov, AA Melnichenko… - Journal of molecular …, 2017 - Springer
Low-density lipoprotein (LDL) and cholesterol homeostasis in the peripheral blood is
maintained by specialized cells, such as macrophages. Macrophages express a variety of …

Macrophage‐mediated cholesterol handling in atherosclerosis

DA Chistiakov, YV Bobryshev… - Journal of cellular and …, 2016 - Wiley Online Library
Formation of foam cells is a hallmark at the initial stages of atherosclerosis. Monocytes
attracted by pro‐inflammatory stimuli attach to the inflamed vascular endothelium and …

[HTML][HTML] The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis

Y Waumans, L Baerts, K Kehoe, AM Lambeir… - Frontiers in …, 2015 - frontiersin.org
Research from over the past 20 years has implicated dipeptidyl peptidase (DPP) IV and its
family members in many processes and different pathologies of the immune system. Most …

DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition

J Zhong, A Maiseyeu, SN Davis… - Circulation …, 2015 - Am Heart Assoc
The discovery of incretin-based medications represents a major therapeutic advance in the
pharmacological management of type 2 diabetes mellitus (T2DM), as these agents avoid …

NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis

Z Wan, Y Fan, X Liu, J Xue, Z Han, C Zhu… - … Syndrome and Obesity …, 2019 - Taylor & Francis
Background NLRP3 inflammasome can be activated by high glucose and links inflammation
and metabolic disease. This study aimed to investigate the role of NLRP3 inflammasome in …

[HTML][HTML] DPP-4 inhibitors and GLP-1RAs: Cardiovascular safety and benefits

M Razavi, YY Wei, XQ Rao, JX Zhong - Military Medical Research, 2022 - Springer
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are
commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti …

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

Y Tashiro, K Sato, T Watanabe, K Nohtomi, M Terasaki… - Peptides, 2014 - Elsevier
Macrophage foam cell formation, characterized by cholesterol ester accumulation catalyzed
by acyl-CoA: cholesterol acyltransferase 1 (ACAT1), is the hallmark of early atherogenesis …

[HTML][HTML] Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell …

M Terasaki, M Hiromura, Y Mori, K Kohashi… - PloS one, 2015 - journals.plos.org
Direct associations between hyperglycemia and atherosclerosis remain unclear. We
investigated the association between the amelioration of glycemia by sodium-glucose …

DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway

Y Dai, D Dai, X Wang, Z Ding, JL Mehta - Cardiovascular drugs and …, 2014 - Springer
Background Anti-atherosclerotic effects of dipeptidyl peptidase-4 (DPP-4) inhibitors have
been shown in many studies. Since inflammation and immune response play a key role in …

Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms

A Ahmadi, Y Panahi, TP Johnston, A Sahebkar - Pharmacological research, 2021 - Elsevier
Cardiovascular disease is one of the leading causes of mortality globally. Atherosclerosis is
an important step towards different types of cardiovascular disease. The role of oxidized low …